Ratify (Alliance 10603): Prognostic Impact of FLT3 Tyrosine Kinase Domain (TKD) and NPM1 Mutation Status in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Treated with Midostaurin Plus Standard Chemotherapy
      Google Scholar   
Citation:
HemaSphere vol 3 (suppl 1) 79-80
Meeting Instance:
EHA 2019
Year:
2019
Type:
Abstract
Sub type:
Poster Discussion
Funding:
NCTN
Endpoint:
Secondary-not-in-original
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
epub
Note:
Methodological:
No
Biospecimen:
Yes
SDC:
No
Parents:
None
Children:
3327  
Program:
OGC
Primary Committee:
Leukemia
Sec. Committees:
   
Pharmas:
Novartis  
Grants:
U10CA180821, U10CA180882, U24CA196171  
Corr. Author:
 
Authors:
                                                                   
Networks:
CA043, LAPS-IL036, LAPS-IL057, LAPS-MA036, LAPS-OH007   
Study
CALGB-10603
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords: